|
|
|
|
|
|
Sponsors and Collaborators: |
Manhattan Eye, Ear & Throat Hospital Alcon Research |
Information provided by: | Manhattan Eye, Ear & Throat Hospital |
ClinicalTrials.gov Identifier: | NCT00211406 |
The purpose of this study is to provide compassionate use of anecortave acetate sterile suspension of 15 mg for a series of five patients as a means to control diabetic retinopathy.
Condition | Intervention | Phase |
Diabetic Retinopathy |
Drug: Anecortave Acetate Sterile Suspension (15 mg) |
Phase I |
MedlinePlus related topics: | Diabetic Eye Problems Retinal Disorders |
ChemIDplus related topics: | Anecortave acetate |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Inclusion Criteria:
Exclusion Criteria:
United States, New York | |||||
Manhattan Eye, Ear & Throat Hospital | |||||
New York, New York, United States, 10021 |
Manhattan Eye, Ear & Throat Hospital |
Alcon Research |
Principal Investigator: | Lawrence Yannuzzi, MD | Manhattan Eye, Ear & Throat Hospital |
Study ID Numbers: | Diabetic Retinopathy |
First Received: | September 13, 2005 |
Last Updated: | May 6, 2007 |
ClinicalTrials.gov Identifier: | NCT00211406 |
Health Authority: | United States: Food and Drug Administration |
|
|
|